Global COVID-19 vaccine maker Pfizer Inc. published its Q3 earnings report on Tuesday before the market opened. The firm’s Revenue grew 7% operationally to $11.1 billion and recorded a diluted EPS of $1.42.
Key Highlights
- Third-Quarter 2021 Revenues of $24.1 Billion, Reflecting 130% Operational Growth; Excluding Comirnaty(1), Revenues Grew 7% Operationally to $11.1 Billion.
- Third-Quarter 2021 Reported Diluted EPS(2) of $1.42, Adjusted Diluted EPS(3) of $1.34.
- Raises Full-Year 2021 Guidance(4) for Revenues to a Range of $81.0 to $82.0 Billion and Adjusted Diluted.
- EPS(3) to a Range of $4.13 to $4.18, Reflecting 94% and 84% Year-Over-Year Growth at the Midpoints, respectively.
- Anticipates 2021 Revenues of Approximately $36 Billion for Comirnaty(1), 2.3 Billion Doses expected to be delivered in Fiscal 2021
- Raises Midpoint of Guidance for Adjusted Diluted EPS(3) excluding Comirnaty(1) to a range of $2.60 to $2.65
Analysts Estimate
EPS: $1.09
Revenue: $22.82 billion
The company reported EPS of $0.72 for the same quarter last year.
While we are proud of our third quarter financial performance, we are even more proud of what these financial results represent in terms of the positive impact we are having on human lives around the world. For example, more than 75% of the revenues we have recorded up through third-quarter 2021 for Comirnaty(1) have come from supplying countries outside the U.S., and we remain on track to achieve our goal of delivering at least two billion doses to low- and middle-income countries by the end of 2022 — at least one billion to be delivered this year and one billion next year, with the possibility to increase those deliveries if more orders are placed by these countries for 2022. One billion of these doses will be supplied to the U.S. government at a not-for-profit price to be donated to the world’s poorest nations at no charge to those countries. Despite all we have been able to accomplish to date, we remain focused on our future, not our past. Our ultimate goal is to help bring this pandemic to an end as quickly as possible, but also to apply the lessons we have learned through our work on the vaccine to all of our therapeutic areas. We look forward to providing future updates on these efforts.”
Dr. Albert Bourla, Chairman and Chief Executive Officer.
Earnings History
Healthcare company Pfizer last released its earnings report on 28th July, 2022 for quarter 2. It reported an EPS of $1.07 and revenue of $19.0 billion, 60.81% YOY. The revenues grew 10% operationally to $11.1 billion. It raised 2021 guidance above estimates on strong COVID-19 vaccine sales.
Annual Forecast
EPS
For 2021- $4.06
For 2022- $3.72
Revenue
For 2021- 81.56 billion
For 2022- 69.88 billion
Forward PE
For 2021- 10.62
For 2022- 11.62
FWD Price/Sale
For 2021- 2.97
For 2022- 3.46
Plans
COVID-19 vaccine maker Pfizer has various other medicines in development. It aims to address unmet needs of a number of important therapeutic areas such as Oncology, Inflammation & Immunology, Vaccines, Internal Medicine and Rare disease in order to benefit patients around the world.
Company Profile
Pfizer Inc., a multinational pharmaceutical and biotechnology corporation is registered in America on 42nd street in Manhattan, New York City. It was founded by two German immigrants, Charles Pfizer and Charles F. Erhart. As of 2020, the company has total assets of $178.983 billion, operating income of $8.16 billion and revenue of $41.90 billion.
Pfizer collaborated with BioNTech, a German company for development of COVID-19 vaccine, called Comirnaty. It is an mRNA based vaccine, authorized for use in people aged twelve years and old in some jurisdictions and sixteen years and above people in other jurisdictions.
